Literature DB >> 9861564

Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.

M Oethinger1, A S Jellen-Ritter, S Conrad, R Marre, W V Kern.   

Abstract

Escherichia coli with high-level fluoroquinolone resistance were isolated from feces and/or various body sites of 16 cancer patients who were on oral fluoroquinolone prophylaxis. Population analysis of fecal isolates in 11 patients showed that fluoroquinolone-resistant E. coli was the only aerobic gram-negative bacillus present and exhibited a relatively homogenous fluoroquinolone MIC distribution. Molecular typing by pulsed field gel electrophoresis of chromosomal DNA digests or by random amplified polymorphic DNA fingerprinting confirmed the clonal nature of gastrointestinal tract colonization with E. coli. Genotyping of ten colonies picked from the same fecal culture demonstrated identical strains in four of four patients examined. Identical genotypes from the same patient were isolated over prolonged periods of time in 12 of 12 cases examined, with one patient (with the longest follow-up of 14 months) who lost his initial genotype and became persistently colonized with a new genotype. In the 11 patients who developed infection due to fluoroquinolone-resistant E. coli, molecular typing also indicated that fecal colonization was associated with, and presumably preceded infection due to an indistinguishable genotype of fluoroquinolone-resistant E. coli.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9861564     DOI: 10.1007/bf02770840

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  22 in total

1.  Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer--is it justified?

Authors:  M Murphy; A E Brown; K A Sepkowitz; E M Bernard; T E Kiehn; D Armstrong
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

2.  Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains.

Authors:  L J Piddock; M C Hall; R N Walters
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790

3.  Effect of oral ofloxacin on fecal bacteria in human volunteers.

Authors:  S Pecquet; A Andremont; C Tancrède
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

4.  Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection.

Authors:  K J Henning; H Delencastre; J Eagan; N Boone; A Brown; M Chung; N Wollner; D Armstrong
Journal:  Pediatr Infect Dis J       Date:  1996-10       Impact factor: 2.129

5.  RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing related bacterial strains.

Authors:  G Wang; T S Whittam; C M Berg; D E Berg
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

6.  Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia.

Authors:  A Cometta; T Calandra; J Bille; M P Glauser
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

7.  Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers.

Authors:  D A Leigh; B Walsh; K Harris; P Hancock; G Travers
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

8.  Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.

Authors:  J Carratala; A Fernandez-Sevilla; F Tubau; M A Dominguez; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora.

Authors:  S Pecquet; A Andremont; C Tancrède
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

10.  Resolution of recent evolutionary divergence among Escherichia coli from related lineages: the application of pulsed field electrophoresis to molecular epidemiology.

Authors:  R D Arbeit; M Arthur; R Dunn; C Kim; R K Selander; R Goldstein
Journal:  J Infect Dis       Date:  1990-02       Impact factor: 5.226

View more
  8 in total

1.  Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.

Authors:  W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

2.  The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Xiangqun Mao; Xiaoyan Han; Neil O Fishman; Warren B Bilker; Pam Tolomeo; Mary Wheeler; Irving Nachamkin
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Prolonged carriage of resistant E. coli by returned travellers: clonality, risk factors and bacterial characteristics.

Authors:  B A Rogers; K J Kennedy; H E Sidjabat; M Jones; P Collignon; D L Paterson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-07       Impact factor: 3.267

4.  Duration of outpatient fecal colonization due to Escherichia coli Isolates with decreased susceptibility to fluoroquinolones: longitudinal study of patients recently discharged from the hospital.

Authors:  Ebbing Lautenbach; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Joshua P Metlay; Warren B Bilker; Irving Nachamkin
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

Review 5.  Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.

Authors:  Rachel M Greenblatt; Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-21       Impact factor: 3.254

6.  Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.

Authors:  David M Livermore; Dorothy James; Mark Reacher; Catriona Graham; Thomas Nichols; Peter Stephens; Alan P Johnson; Robert C George
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

7.  Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Mark G Weiner; Warren B Bilker; Pam Tolomeo; Xiangqun Mao; Irving Nachamkin; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-01       Impact factor: 3.254

Review 8.  Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia.

Authors:  Sarah P Hammond; Lindsey R Baden
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 4.213

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.